Download PDF
Exp Clin Endocrinol Diabetes 2020; 128(09): 567-572
DOI: 10.1055/a-0915-1982
Article

Disease Activity May Not Affect the Prognosis of Coexisting Thyroid Cancer in Acromegalic Patients

Nurdan Gul
1   Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Çapa, Istanbul, Turkey
,
Ozlem Soyluk
1   Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Çapa, Istanbul, Turkey
,
Sema Ciftci Dogansen   *
1   Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Çapa, Istanbul, Turkey
,
Neslihan Kurtulmus
2   Maslak Hospital, Division of Endocrinology and Metabolism, Acibadem University, Maslak, Istanbul, Turkey
,
Sema Yarman
1   Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul University, Istanbul Faculty of Medicine, Çapa, Istanbul, Turkey
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Acromegaly is known to be associated with high incidence of malignancies probably due to the mitogenic effects of IGF-1. Differentiated thyroid cancer (DTC) is reported to be one of the most frequent malignancies associated with acromegaly. But there is no data about the clinical course of DTC in acromegalic patients. In this study, we evaluated the course of DTC in 14 acromegalic patients retrospectively. Fourteen papillary thyroid cancer patients without acromegaly, who were matched with the acromegalic patient group for age, gender and properties of thyroid cancer, were investigated as the control group. We identified no change in the course and treatment responses of DTC in association with the acromegaly activity, gender, age and disease duration, and all patients were found to be in remission for DTC at the time of investigation. Retrospective analysis of this cohort suggests that the activity of acromegaly may not affect the treatment responses and prognosis of coexisting DTC.

Key words

acromegaly - differentiated thyroid cancer - activity of acromegaly - prognosis of thyroid cancer

* Present Address
Bakırkoy Dr. Sadi Konuk Training and Research Hospital,
Bakırkoy, 34147 Istanbul,
Turkey




Publication History

Received: 10 January 2019
Received: 09 April 2019

Accepted: 07 May 2019

Article published online:
11 June 2019

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Kopchick JJ, List EO, Kelder B. et al. Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications. Mol Cell Endocrinol 2014; 386: 34-45
    CrossrefPubMedGoogle Scholar
  • 2 Boguszewski CL, Ayuk J. Management of Endocrine Disease: Acromegaly and cancer: An old debate revisited. Eur J Endocrinol 2016; 175: 147-156
    CrossrefPubMedGoogle Scholar
  • 3 Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011; 7: 11-24
    CrossrefPubMedGoogle Scholar
  • 4 Chi F, Wu R, Zeng YC. et al. Circulation insulin-like growth factor peptides and colorectal cancer risk: An updated systematic review and meta-analysis. Mol Biol Rep 2013; 40: 3583-3590
    CrossrefPubMedGoogle Scholar
  • 5 Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-152
    CrossrefPubMedGoogle Scholar
  • 6 Loeper S, Ezzat S. Acromegaly: Re-thinking the cancer risk. Rev Endocr Metab Disord 2008; 9: 41-58
    CrossrefPubMedGoogle Scholar
  • 7 Melmed S. Acromegaly and cancer: Not a problem?. J Clin Endocrinol Metab 2001; 86: 2929-2934
    CrossrefPubMedGoogle Scholar
  • 8 Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010; 13: 242-248
    CrossrefPubMedGoogle Scholar
  • 9 Dagdelen S, Cinar N, Erbas T. Increased thyroid cancer risk in acromegaly. Pituitary 2014; 17: 299-306
    CrossrefPubMedGoogle Scholar
  • 10 Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly – meta-analysis and systematic review. PLoS ONE 2014; 14 9(2) e88787
    CrossrefPubMedGoogle Scholar
  • 11 Tode B, Serio M, Rotella CM. et al. Insulin-like growth factor-I: Autocrine secretion by human thyroid follicular cells in primary culture. J Clin Endocrinol Metab 1989; 69: 639-647
    CrossrefPubMedGoogle Scholar
  • 12 Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 1988; 66: 1158-1165
    CrossrefPubMedGoogle Scholar
  • 13 Derwahl M, Broecker M, Kraiem Z. Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab 1999; 84: 829-834
    PubMedGoogle Scholar
  • 14 Yashiro T, Ohba Y, Murakami H. et al. Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinol (Copenh) 1989; 121: 112-120
    CrossrefPubMedGoogle Scholar
  • 15 Katznelson L, Laws ER, Melmed S. et al. Endocrine Society. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
    CrossrefPubMedGoogle Scholar
  • 16 Muhammad A, van der Lely AJ, Delhanty PJD. et al. Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study). J Clin Endocrinol Metab 2018; 103: 586-595
    CrossrefPubMedGoogle Scholar
  • 17 Wolinski K, Stangierski A, Dyrda K. et al. Risk of malignant neoplasms in acromegaly: A case-control study. J Endocrinol Invest 2017; 40: 319-322
    CrossrefPubMedGoogle Scholar
  • 18 Aydin K, Aydin C, Dagdelen S. et al. Genetic alterations in differentiated thyroid cancer patients with acromegaly. Exp Clin Endocrinol Diabetes 2016; 124: 198-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008; 159: 89-95
    CrossrefPubMedGoogle Scholar
  • 20 Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-2734
    PubMedGoogle Scholar
  • 21 Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89: 667-674
    CrossrefPubMedGoogle Scholar
  • 22 Petroff D, Tönjes A, Grussendorf M. et al. The incidence of cancer among acromegaly patients: Results from the German Acromegaly Registry. J Clin Endocrinol Metab 2015; 100: 3894-3902
    CrossrefPubMedGoogle Scholar
  • 23 Liu Z, Zeng W, Chen T. et al. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: A meta-analysis. Oncotarget 2017; 8: 6222-6232
    CrossrefPubMedGoogle Scholar
  • 24 Haugen BR, Alexander EK, Bible KC. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26: 1-133
    CrossrefPubMedGoogle Scholar